Literature DB >> 437245

Effects of murine tumor necrosis factor on heterotransplanted human tumors.

L Helson, C Helson, S Green.   

Abstract

A partially purified glycoprotein fraction (the G-200 II fraction) obtained from sera of CD-1 mice sensitized with Corynebacterium parvum and treated with endotoxin was designated as tumor necrosis factor (TNF). Human melanoma cells exposed to this factor in vitro had decreased tumorigenicity when injected into nude mice. Human melanoma, embryonal adenocarcinoma of the testis and colon carcinoma heterotransplanted in nude mice exhibited regressions in size following intraperitoneal injections of TNF. The responses were related to dose and duration of exposure.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 437245     DOI： 10.1159/000162922

Source DB:  PubMed          Journal:  Exp Cell Biol        ISSN： 0304-3568


  12 in total

1.  Recombinant human tumor necrosis factor mediates regression of a murine sarcoma in vivo via Lyt-2+ cells.

Authors:  A L Asher; J J Mulé; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Tuftsin induced tumor necrosis activity.

Authors:  M S Wleklik; M Luczak; V A Najjar
Journal:  Mol Cell Biochem       Date:  1987-06       Impact factor: 3.396

3.  Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.

Authors:  A L Asher; J J Mulé; A Kasid; N P Restifo; J C Salo; C M Reichert; G Jaffe; B Fendly; M Kriegler; S A Rosenberg
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

Review 4.  Tumor necrosis factor-alpha-converting enzyme activities and tumor-associated macrophages in breast cancer.

Authors:  Stephen L Rego; Rachel S Helms; Didier Dréau
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

5.  Tumour necrosis factor and the lysosomal enzymes of macrophages or macrophage-like cell line.

Authors:  A Sakurai; N Satomi; K Haranaka
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

6.  Specificity of tumor necrosis factor toxicity for human mammary carcinomas relative to normal mammary epithelium and correlation with response to doxorubicin.

Authors:  C Dollbaum; A A Creasey; S H Dairkee; A J Hiller; A R Rudolph; L Lin; C Vitt; H S Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

7.  Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy.

Authors:  J J Mulé; A Asher; J McIntosh; R Lafreniere; E Shiloni; A Lefor; C M Reichert; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

8.  Role of first stimulating agents in the production of tumor necrosis factor.

Authors:  K Haranaka; N Satomi; A Sakurai; R Haranaka
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

9.  Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer.

Authors:  D Azria; C Larbouret; V Garambois; A Kramar; P Martineau; B Robert; N Aillères; M Ychou; J B Dubois; A Pèlegrin
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

10.  Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors.

Authors:  N Watanabe; T Okamoto; N Tsuji; H Sasaki; S Akiyama; D Kobayashi; T Sato; N Yamauchi; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1995-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.